Skip to main content

Table 2 Number of fixed health facilities providing diagnosis and treatment for gambiense HAT

From: Mapping the capacities of fixed health facilities to cover people at risk of gambiense human African trypanosomiasis

  Diagnosis Treatment Total
  DxC DxS DxP DxPh Total Dx Tx1P Tx2M Tx2E Tx2N Total Tx2 Total Tx  
Angola* 19 19 18 17 19 17 12 13 0 13 17 19
Benin 3 3 0 0 3 0 0 0 0 0 0 3
Burkina Faso 2 2 2 1 2 1 1 1 0 1 1 2
Cameroon 8 0 7 7 8 9 6 5 5 6 9 9
Central African Republic 11 9 9 9 11 10 8 7 7 8 10 11
Chad 4 4 4 4 4 10 4 4 4 4 10 10
Congo 10 10 8 7 10 9 5 3 3 5 9 10
Côte d’Ivoire 4 4 1 1 4 4 1 1 1 1 4 4
Democratic Republic of the Congo 524 273 229 173 524 404 147 144 144 147 404 524
Equatorial Guinea 5 1 4 1 5 4 1 1 1 1 4 5
Gabon 1 1 1 1 1 4 2 2 2 2 4 4
Ghana 1 0 0 0 1 1 0 0 0 0 1 1
Guinea 3 2 2 2 3 2 1 1 1 1 2 3
Mali 6 1 1 1 6 1 1 1 1 1 1 6
Nigeria 5 5 5 5 5 5 5 0 0 5 5 5
Sierra Leone 0 0 0 0 0 0 0 0 0 0 0 0
South Sudan 10 6 7 7 10 10 7 7 7 7 10 10
Togo 2 2 0 0 2 0 0 0 0 0 0 2
Uganda 4 4 4 4 4 4 4 4 4 4 4 4
Total 622 346 302 240 622 495 205 194 180 206 495 632
  1. Study area: disease-endemic countries having reporting cases or having conducted active screening activities during the period 2000-2012. DxC: clinical diagnosis; DxS: serological diagnosis; DxP: parasitological diagnosis; DxPh: disease staging. Tx1P: treatment of first-stage infection with pentamidine; Tx2M: treatment of second-stage infection with melarsoprol; Tx2E: treatment of second-stage infection with eflornithine; Tx2N: treatment of second-stage infection with nifurtimox-eflornithine combination therapy (NECT); Tx2: treatment of second stage.
  2. *After closing the study, information was received that Angola upgraded the Tx2E centres to Tx2N.